Newsbenzinga
RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…